<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921765</url>
  </required_header>
  <id_info>
    <org_study_id>DOK-018</org_study_id>
    <nct_id>NCT00921765</nct_id>
  </id_info>
  <brief_title>Reversal of Ketamine Pharmacodynamic Effects With Naloxone</brief_title>
  <official_title>Naloxone Block of Low-dose (Analgetic Dose) Ketamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the analgetic and other effects effect of
      ketamine are partly mediated through opioid receptors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketamine er et dissociative anaesthetic closely related with phencyclidine (PCP).
      Phencyclidine is a non-competitive NMDA-antagonist, and it is assumed that the
      pharmacodynamic mechanism of action for ketamine is the same. Receptor binding studies shows
      that ketamine has affinity to many receptor types, including opioid mu and kappa receptors.
      Ketamine has only about 25 times lower affinity for kappa receptors than for the
      NMDA-receptor complex. Naloxone is a specific antagonist for opioid receptors and block both
      mu og kappa receptors. A dose of naloxone 10 times larger than required to block mu receptors
      is required to block kappa receptors. Experiments with naloxone suggest that ketamine is not
      a mu agonist, but experiments with sufficient large naloxone doses to block kappa receptors
      have not been carried out in humans.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Problems with patient recruitment
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallell Group design should be used when final dose had been found</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind (one making drug solutions) another administrating the drugs</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity (0-10 Numerical Rating Scale)</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective measurement of psychotomimetic effects</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline single bolus dose iv + saline single bolus dose iv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saline single bolus dose followed by single bolus dose of ketamine 0.2 mg/kg bw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxone + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxone + Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single bolus dose of ketamine 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline single bolus dose followed by saline single bolus dose iv</description>
    <arm_group_label>Placebo + Placebo</arm_group_label>
    <other_name>Physiological saline 0.9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline + Ketamine</intervention_name>
    <description>Single bolus dose of saline followed by ketamine 0.2 mg/kg bw</description>
    <arm_group_label>Placebo + Ketamine</arm_group_label>
    <other_name>Physiological saline 0.9%</other_name>
    <other_name>Ketamine</other_name>
    <other_name>ATC code: N01A X03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone + Placebo</intervention_name>
    <description>Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline</description>
    <arm_group_label>Naloxone + Placebo</arm_group_label>
    <other_name>Naloxone</other_name>
    <other_name>ATC code: V03A B15</other_name>
    <other_name>Physiological saline 0.9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone + Ketamine</intervention_name>
    <description>Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw</description>
    <arm_group_label>Naloxone + Ketamine</arm_group_label>
    <other_name>Naloxone</other_name>
    <other_name>ATC code: V03A B15</other_name>
    <other_name>Ketamine</other_name>
    <other_name>ATC code: N01A X03</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females of norwegian Caucasian origin who needs surgical removal of impacted third
             molars

        Exclusion Criteria:

          -  Anamnestic information regarding psychiatric diagnosis regarding mother/father or
             brother/sister Concommitant medication other than oral contraceptives Hypersensitivity
             towards NSAID/opioids/study drugs Females with suspected or confirmed pregnancy
             Lactating females Surgery lasting more than 60 minutes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olav Hustveit, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Landari, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ullevaal University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD. Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med. 1996 Nov;2(11):1248-50.</citation>
    <PMID>8898754</PMID>
  </reference>
  <reference>
    <citation>Hustveit O, Maurset A, Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9.</citation>
    <PMID>8835358</PMID>
  </reference>
  <reference>
    <citation>Mathisen LC, Skjelbred P, Skoglund LA, Oye I. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain. 1995 May;61(2):215-20.</citation>
    <PMID>7659431</PMID>
  </reference>
  <reference>
    <citation>Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992 Mar;260(3):1209-13.</citation>
    <PMID>1312163</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2009</study_first_submitted>
  <study_first_submitted_qc>June 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Lasse Ansgar Skoglund</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Naloxone</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Third Molar</keyword>
  <keyword>Surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

